GV101
Clinical-stage small molecule therapeutic
Oral, potent and selective ROCK2 inhibitor in clinical development for Friedreich's ataxia, which has also been studied for weight loss in obesity.
- Oral selective ROCK2 inhibitor
- FDA Fast Track designation for Friedreich's ataxia
- IND cleared, Phase 2 dose-ranging study starting
- Phase 2 obesity trial registered
Built for
Patients with fibrotic, autoimmune and CNS diseases, and pharma partners